Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07081646 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
A Phase 1 study of Amyloidosis and Refractory AL Amyloidosis, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 18
- Study locations
NCT07081646: Recruiting Phase 1 study of Amyloidosis and Refractory AL Amyloidosis, sponsored by Alexion Pharmaceuticals.
NCT07081646 is a Phase 1 study of Amyloidosis and Refractory AL Amyloidosis that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 91 participants, below the 1,126-participant average among 28 other Amyloidosis trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07081646, a Phase 1 study of Amyloidosis and Refractory AL Amyloidosis, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 18
- Study locations
Study Summary
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Conditions Studied
Interventions
- DRUG AZD0120
Study Locations (18)
New York
- Research Site - New York
- Research Site - New York
- Research Site - New York
Alberta
- Research Site - Calgary
- Research Site - Calgary
Ontario
- Research Site - Toronto
- Research Site - Toronto
Other
- Research Site - London
- Research Site - London
Arizona
- Research Site - Phoenix
California
- Research Site - San Francisco
Florida
- Research Site - Tampa
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2031-02-14 |
| Phase | Phase 1 |
What NCT07081646 shows while recruiting
NCT07081646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 1,126-participant average among 28 other Amyloidosis trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which AZD0120 is the first listed.
NCT07081646 lists 18 locations in 13 states (New York, Alberta, Ontario).
Frequently Asked Questions
What is clinical trial NCT07081646 about?
NCT07081646 is a clinical study titled "A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.". Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
What is the current status of trial NCT07081646?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2025-08-18. Estimated completion is 2031-02-14.
What conditions does trial NCT07081646 study?
This clinical trial studies the following conditions: Amyloidosis, Refractory AL Amyloidosis, Relapsed AL Amyloidosis, Light Chain Amyloidosis.
What interventions are being tested in trial NCT07081646?
The interventions under investigation include: AZD0120 (DRUG).
Who is sponsoring clinical trial NCT07081646?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07081646 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07081646's enrollment target sits among peer trials
91 14th of 28 higher than 15 of 28 other Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
RECRUITING · Phase 1
-
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
ACTIVE NOT RECRUITING · Phase 1
-
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
COMPLETED · Phase 1
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI